235 related articles for article (PubMed ID: 33309571)
1. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
4. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis.
Roy B; Das A; Ashish K; Bandyopadhyay D; Maiti A; Chakraborty S; Stone ME; Philpotts LL; Nowak RJ; Patwa HS
Neurology; 2019 Jul; 93(2):e143-e148. PubMed ID: 31167931
[TBL] [Abstract][Full Text] [Related]
5. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
7. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
Chen YC; Chen JH; Hsieh FI
J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract][Full Text] [Related]
9. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
[No Abstract] [Full Text] [Related]
10. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
[TBL] [Abstract][Full Text] [Related]
11. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
Ding F; Liu B; Wang Y
J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
Qi WX; Min DL; Shen Z; Sun YJ; Lin F; Tang LN; He AN; Yao Y
Int J Cancer; 2013 Jun; 132(12):2967-74. PubMed ID: 23225494
[TBL] [Abstract][Full Text] [Related]
13. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Li J; Gu J
Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
Zhang W; Feng LJ; Teng F; Li YH; Zhang X; Ran YG
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):311-320. PubMed ID: 32105149
[No Abstract] [Full Text] [Related]
15. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.
Qi WX; Shen Z; Tang LN; Yao Y
Br J Clin Pharmacol; 2014 Oct; 78(4):748-62. PubMed ID: 24661224
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.
Qi WX; Tang LN; Sun YJ; He AN; Lin F; Shen Z; Yao Y
Ann Oncol; 2013 Dec; 24(12):2943-52. PubMed ID: 23921791
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
Massey PR; Okman JS; Wilkerson J; Cowen EW
Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
[TBL] [Abstract][Full Text] [Related]
18. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
[TBL] [Abstract][Full Text] [Related]
19. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.
Li J; Gu J
Eur J Clin Pharmacol; 2017 Oct; 73(10):1209-1217. PubMed ID: 28710508
[TBL] [Abstract][Full Text] [Related]
20. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Ghatalia P; Je Y; Kaymakcalan MD; Sonpavde G; Choueiri TK
Br J Cancer; 2015 Jan; 112(2):296-305. PubMed ID: 25349964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]